PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 27.27

Change

+0.34 (+1.26)%

Market Cap

N/A

Volume

0.68M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.15 (+0.20%)

USD 13.78B
DOCS Doximity Inc

-1.12 (-1.79%)

USD 13.23B
WEAV Weave Communications Inc

-0.33 (-2.88%)

USD 0.83B
AMWL American Well Corp

-0.33 (-4.02%)

USD 0.16B
CTEV Claritev Corporation

-0.05 (-0.25%)

N/A
EVH Evolent Health Inc

+0.15 (+1.50%)

N/A
TDOC Teladoc Inc

-0.48 (-5.41%)

N/A
VEEV Veeva Systems Inc Class A

-0.53 (-0.22%)

N/A
FOXO FOXO Technologies Inc.

-0.01 (-5.11%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.39% 56% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.39% 56% F 85% B
Trailing 12 Months  
Capital Gain 17.64% 88% B+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.64% 88% B+ 81% B-
Trailing 5 Years  
Capital Gain 47.17% 50% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.17% 50% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain 6.21% 67% D+ 54% F
Dividend Return 6.21% 67% D+ 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.47% 67% D+ 14% F
Risk Adjusted Return 9.94% 78% C+ 27% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector